Featured Research

from universities, journals, and other organizations

Propranolol associated with improvement in size and color of head and neck hemangiomas in children

Date:
May 16, 2011
Source:
JAMA and Archives Journals
Summary:
The beta-blocker propranolol appears to be associated with reducing the size and color of hemangiomas of the head and neck in a pediatric population, according to a new study.

The beta-blocker propranolol appears to be associated with reducing the size and color of hemangiomas of the head and neck in a pediatric population, according to a report in the May issue of Archives of Otolaryngology-Head and Neck Surgery, one of the JAMA/Archives journals.

Related Articles


According to background information in the article, hemangiomas are tumors that appear by the age of 2 months, affecting up to 10 percent of full-term white infants. These lesions can be benign, or can affect functions such as the ability to see or on occasion can be life-threatening if they occur in areas such as airways. Although 70 percent of infantile hemangiomas regress by age 7 years, they may leave behind scars or fibrous fatty tissue. Oral corticosteroids have long been the treatment of choice for this condition, although they may be associated with some significant adverse effects. Three years ago, researchers learned that propranolol could serve as a treatment for hemangiomas in babies, and formal studies of the drug were then launched.

Carine Fuchsmann, M.D., from Hospices Civils de Lyon in Bron , France and colleagues reviewed the records of 39 children treated with propranolol for head and neck hemangiomas that had complications, threatened function or appearance or occurred in life-threatening locations. The assessment included clinical examinations, photographs, and echographic evaluations of the tumors. In 16 patients, previous treatment was either unsuccessful or associated with relapses.

In 37 of the hemangiomas, propranolol therapy was associated with improvement within two weeks. Overall, the authors note, "improvement was not only in the size but also in the quality of the lesion, which flattened and changed color." This included 26 tumors that would not otherwise have been appropriate for treatment with corticosteroids. In six cases, following treatment the tumors recurred, but another course of the drug was effective. Five patients were switched to another beta-blocker due to sleep disturbances.

The authors point out that in some patients the drug may be better tolerated than corticosteroids, and that it can be particularly helpful for "treatment of hemangiomas in locations that previously did not benefit from medical therapy because of possible adverse effects." They call for further studies to establish dosing and treatment-cessation protocols, and also to establish whether other beta-blockers can be acceptable substitutes.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Fuchsmann, M.-C. Quintal, C. Giguere, S. Ayari-Khalfallah, L. Guibaud, J. Powell, C. McCone, P. Froehlich. Propranolol as First-line Treatment of Head and Neck Hemangiomas. Archives of Otolaryngology - Head and Neck Surgery, 2011; 137 (5): 471 DOI: 10.1001/archoto.2011.55

Cite This Page:

JAMA and Archives Journals. "Propranolol associated with improvement in size and color of head and neck hemangiomas in children." ScienceDaily. ScienceDaily, 16 May 2011. <www.sciencedaily.com/releases/2011/05/110516161936.htm>.
JAMA and Archives Journals. (2011, May 16). Propranolol associated with improvement in size and color of head and neck hemangiomas in children. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2011/05/110516161936.htm
JAMA and Archives Journals. "Propranolol associated with improvement in size and color of head and neck hemangiomas in children." ScienceDaily. www.sciencedaily.com/releases/2011/05/110516161936.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com
Doctors Often Give In To Vaccine-Wary Parents

Doctors Often Give In To Vaccine-Wary Parents

Newsy (Mar. 2, 2015) A new survey published in the journal Pediatrics found many doctors are giving in to parents&apos; requests to delay vaccinating their children. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins